SS-31 vs Humanin

Overview

SS-31 (elamipretide) and Humanin both target mitochondrial function but from different angles. SS-31 is a synthetic peptide in active clinical development that directly binds cardiolipin on the inner mitochondrial membrane, while Humanin is an endogenous mitochondria-derived peptide (MDP) that provides cytoprotection through receptor-mediated signaling. They represent synthetic drug development vs endogenous peptide research approaches.

This comparison highlights the contrast between clinical-stage development and academic research in mitochondrial aging interventions.

Key Facts

Aspect	SS-31 (Elamipretide)	Humanin
Type	Synthetic tetrapeptide	Endogenous MDP
Structure	D-Arg-Dmt-Lys-Phe-NH2	24 amino acids (MAPRGFSCLLLLTSEIDLPVKRRA)
Origin	Designed/synthetic	Mitochondrial DNA-encoded
Developer	Stealth BioTherapeutics	Academic research
Clinical Status	Phase 2/3 trials	No clinical development
FDA Status	Investigational	Not approved

Development Comparison

Aspect	SS-31	Humanin
Discovery	2000s (rational design)	2001 (functional screen)
Research Phase	Clinical trials	Academic/preclinical
Corporate Backing	Yes (Stealth Bio)	No
Patent Protection	Yes	Limited
Path to Market	Active	None

Mechanism Comparison

Aspect	SS-31	Humanin
Primary Target	Cardiolipin (inner membrane)	FPRL1/2 receptors, BAX
Action Site	Mitochondria (direct)	Receptors + mitochondria
Mechanism	Structural optimization	Signaling + direct binding
Effect	Improved ETC efficiency	Anti-apoptotic

SS-31 Mechanisms

1. Cardiolipin Binding

   • Binds inner mitochondrial membrane
   • Optimizes cytochrome c interactions
   • Stabilizes respiratory complexes
   • Reduces electron leak

2. Mitochondrial Concentration

   • 1000-5000x concentration in mitochondria
   • Rapid uptake (minutes)
   • Targets source of ROS
   • Membrane potential-independent

3. Bioenergetic Improvement

   • Increased ATP/O2 ratio
   • Reduced ROS production
   • Protected cristae structure
   • Improved respiration

Humanin Mechanisms

1. Receptor Signaling

   • FPRL1/2 receptor binding
   • ERK1/2 and STAT3 activation
   • Anti-apoptotic gene expression
   • Survival pathway activation

2. BAX Inhibition

   • Direct binding to pro-apoptotic BAX
   • Prevents mitochondrial permeabilization
   • Blocks cytochrome c release
   • Inhibits death cascade

3. Metabolic Effects

   • IGFBP-3 binding
   • Insulin sensitivity effects
   • Metabolic signaling

Evidence Quality

Factor	SS-31	Humanin
Human RCTs	Multiple Phase 2/3	None
Human Safety Data	Established	None
Preclinical Data	Extensive	Extensive
Clinical Development	Active	Not pursued
Overall Evidence	Moderate	Moderate

SS-31 Clinical Evidence

Trial	Phase	Status	Outcome
Barth Syndrome	Phase 2/3	Completed	67m 6MWT improvement
MMPOWER-3 (PMM)	Phase 3	Completed	Primary endpoint not met
PROGRESS-HF	Phase 2	Completed	Trends in LVEF
ReCLAIM (AMD)	Phase 2	Completed	Visual acuity improvement
ReCLAIM-2 (AMD)	Phase 2b	Ongoing	2026 results expected

Humanin Evidence

Study Type	Volume	Quality
Biomarker studies (human)	10+	Low-Moderate
Animal models	40+	Moderate
Cell studies	Extensive	Moderate
Mechanistic research	Extensive	Good

Clinical Applications

SS-31 Clinical Targets

Indication	Status	Rationale
Barth Syndrome	Phase 2/3 (positive)	Cardiolipin defect
Primary mitochondrial myopathy	Phase 3 (mixed)	Mitochondrial dysfunction
Heart failure	Phase 2 (trends)	Cardiac mitochondria
Dry AMD	Phase 2b (ongoing)	Retinal mitochondria
Acute kidney injury	Phase 2	Renal protection

Humanin Research Focus

Area	Evidence	Rationale
Neurodegeneration	Preclinical	Anti-amyloid, cytoprotective
Cardiovascular	Preclinical	Anti-ischemic
Diabetes	Preclinical	Insulin sensitivity
Aging	Biomarker	Declines with age

Administration

Aspect	SS-31	Humanin
Route	Subcutaneous, IV	Injection (research)
Half-life	Hours	Being studied
Stability	Good	Requires careful handling
Pharmaceutical	Clinical grade available	Research grade only

Safety Profiles

SS-31 (From Clinical Trials)

Effect	Incidence	Notes
Injection site reactions	Common	Transient
Headache	Reported	Mild-moderate
Fatigue	Reported	Mild
Generally well-tolerated	Yes	No major safety signals

Humanin (Limited Data)

Concern	Note
Human safety	No clinical data
Anti-apoptotic	Theoretical cancer concern
Endogenous nature	May suggest tolerability
Long-term effects	Unknown

Aging/Longevity Context

SS-31 Aging Research

Finding	Model	Source
Reversed mitochondrial aging	Aged mice (1 hour)	Siegel 2013
Improved muscle function	Aged animals	Multiple
Mitochondrial rejuvenation	Cell/animal	Multiple

Humanin Aging Research

Finding	Model	Source
Declines with age	Humans	Multiple studies
Higher in long-lived families	Human genetics	Cobb 2016
Healthspan effects	Animal models	Multiple

Synergy Potential

Factor	Consideration
Complementary mechanisms	Direct membrane vs signaling
Combined targeting	Structure + function
Interaction data	None
Theoretical benefit	Multi-target mitochondrial support

Regulatory and Availability

Aspect	SS-31	Humanin
FDA Status	Investigational drug	Not approved
Clinical Access	Via trials or named patient	Research only
Research Grade	Available (expensive)	Available
Quality Control	High (clinical trials)	Variable
Cost	Very high	Variable

Development Path Comparison

SS-31 Timeline

Milestone	Status
Discovery/preclinical	Complete
Phase 1	Complete
Phase 2	Multiple completed
Phase 3	Ongoing (Barth, AMD)
Approval	Possible if trials succeed

Humanin Path

Status	Note
Academic research	Active
Clinical development	Not pursued
Commercial interest	Limited
Regulatory path	Not initiated

Summary

Factor	SS-31 (Elamipretide)	Humanin
Type	Synthetic drug	Endogenous peptide
Mechanism	Cardiolipin binding	Receptor/BAX signaling
Clinical Status	Phase 2/3 trials	No development
Human Safety Data	Established	None
Evidence Level	Moderate	Moderate
Regulatory Path	Active	None
Availability	Clinical trials/high cost	Research chemical
Path to Use	Potential approval	Academic research only

Key Takeaways

1. SS-31 is clinical-stage: Active Phase 2/3 trials vs humanin in academic research only
2. Different mechanisms: SS-31 direct membrane targeting vs humanin receptor signaling
3. SS-31 has human data: Established safety profile from trials; humanin has none
4. Both target mitochondria: Complementary approaches to mitochondrial dysfunction
5. SS-31 may gain approval: Barth syndrome and AMD trials ongoing
6. Humanin not being developed: Despite 25 years of research, no clinical path
7. Accessibility differs: SS-31 via trials; humanin as research chemical
8. Cost differs dramatically: SS-31 very expensive; humanin moderate research cost

---

This comparison is for educational purposes only. SS-31 is an investigational drug in clinical trials. Humanin is a research compound. Neither is FDA-approved for any indication.